These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17317146)

  • 1. MeCP2 in Rett syndrome: transcriptional repressor or chromatin architectural protein?
    Chadwick LH; Wade PA
    Curr Opin Genet Dev; 2007 Apr; 17(2):121-5. PubMed ID: 17317146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel alterations in the epigenetic signature of MeCP2-targeted promoters in lymphocytes of Rett syndrome patients.
    Lilja T; Wallenborg K; Björkman K; Albåge M; Eriksson M; Lagercrantz H; Rohdin M; Hermanson O
    Epigenetics; 2013 Mar; 8(3):246-51. PubMed ID: 23348913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MeCP2: structure and function.
    Adkins NL; Georgel PT
    Biochem Cell Biol; 2011 Feb; 89(1):1-11. PubMed ID: 21326358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association by guilt: identification of DLX5 as a target for MeCP2 provides a molecular link between genomic imprinting and Rett syndrome.
    Bapat S; Galande S
    Bioessays; 2005 Jul; 27(7):676-80. PubMed ID: 15954098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MeCP2 dysfunction in Rett syndrome and related disorders.
    Moretti P; Zoghbi HY
    Curr Opin Genet Dev; 2006 Jun; 16(3):276-81. PubMed ID: 16647848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome.
    Horike S; Cai S; Miyano M; Cheng JF; Kohwi-Shigematsu T
    Nat Genet; 2005 Jan; 37(1):31-40. PubMed ID: 15608638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The story of Rett syndrome: from clinic to neurobiology.
    Chahrour M; Zoghbi HY
    Neuron; 2007 Nov; 56(3):422-37. PubMed ID: 17988628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ups and downs of BDNF in Rett syndrome.
    Sun YE; Wu H
    Neuron; 2006 Feb; 49(3):321-3. PubMed ID: 16446133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MeCP2 Rett mutations affect large scale chromatin organization.
    Agarwal N; Becker A; Jost KL; Haase S; Thakur BK; Brero A; Hardt T; Kudo S; Leonhardt H; Cardoso MC
    Hum Mol Genet; 2011 Nov; 20(21):4187-95. PubMed ID: 21831886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MECP2, a multi-talented modulator of chromatin architecture.
    Della Ragione F; Vacca M; Fioriniello S; Pepe G; D'Esposito M
    Brief Funct Genomics; 2016 Nov; 15(6):420-431. PubMed ID: 27296483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype.
    Hoffbuhr KC; Moses LM; Jerdonek MA; Naidu S; Hoffman EP
    Ment Retard Dev Disabil Res Rev; 2002; 8(2):99-105. PubMed ID: 12112735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rett syndrome: from the gene to the disease.
    Matijevic T; Knezevic J; Slavica M; Pavelic J
    Eur Neurol; 2009; 61(1):3-10. PubMed ID: 18948693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glatiramer acetate (GA, Copolymer-1) an hypothetical treatment option for Rett syndrome.
    Ben-Zeev B; Aharoni R; Nissenkorn A; Arnon R
    Med Hypotheses; 2011 Feb; 76(2):190-3. PubMed ID: 20951500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A methyl-CpG-binding protein 2-enhanced green fluorescent protein reporter mouse model provides a new tool for studying the neuronal basis of Rett syndrome.
    Schmid RS; Tsujimoto N; Qu Q; Lei H; Li E; Chen T; Blaustein CS
    Neuroreport; 2008 Mar; 19(4):393-8. PubMed ID: 18287934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-derived neurotrophic factor and Rett syndrome.
    Katz DM
    Handb Exp Pharmacol; 2014; 220():481-95. PubMed ID: 24668484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methyl CpG-binding protein 2 (a mutation of which causes Rett syndrome) directly regulates insulin-like growth factor binding protein 3 in mouse and human brains.
    Itoh M; Ide S; Takashima S; Kudo S; Nomura Y; Segawa M; Kubota T; Mori H; Tanaka S; Horie H; Tanabe Y; Goto Y
    J Neuropathol Exp Neurol; 2007 Feb; 66(2):117-23. PubMed ID: 17278996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of MECP2 mutations in New Zealand Rett syndrome patients.
    Raizis AM; Saleem M; MacKay R; George PM
    N Z Med J; 2009 Jun; 122(1296):21-8. PubMed ID: 19652677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MeCP2 as an Activator of Gene Expression.
    Horvath PM; Monteggia LM
    Trends Neurosci; 2018 Feb; 41(2):72-74. PubMed ID: 29405930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of disease: neurogenetics of MeCP2 deficiency.
    Francke U
    Nat Clin Pract Neurol; 2006 Apr; 2(4):212-21. PubMed ID: 16932552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of DNA-methylation-dependent long gene repression in Rett syndrome.
    Gabel HW; Kinde B; Stroud H; Gilbert CS; Harmin DA; Kastan NR; Hemberg M; Ebert DH; Greenberg ME
    Nature; 2015 Jun; 522(7554):89-93. PubMed ID: 25762136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.